BACK ISSUES of PULLAN'S PIECES 

 

November 2024 - Pullan's Pieces #209
Linda: Big Pharma Immunology in Preclinical and Discovery
Linda:  Deals are down! 
Kristine:  Obesity therapeutics
Trevor:  XBI better than S&P

October 2024 - Pullan's Pieces #208
Linda:  The Pfizer Activist Challenge
Linda:  How competitive is partnering your drug?
Kristine:  Investing in Private Biotechs
Trevor:  Betting on everything

September 2024 - Pullan's Pieces #207
Linda: Where are the drugs?
Linda:  China snapshot
Kristine:  Novel targets in Alzheimer's and Parkinson's
Trevor:  Rate cut and XBI falls

August 2024- Pullan's Pieces #206
Linda: Early-stage fund-raising remains hard
Linda:  Licensing and M&A uneven
Kristine:  The IRA and Orphan Drugs
Trevor:  More optimism?

July 2024- Pullan's Pieces #205
Linda: Where are the sales?
Linda:  Your BATNA  
Kristine:  Pharma Option and License Deals
Trevor:  Head and Shoulders?

June 2024- Pullan's Pieces #204
Linda: MASH- the old NASH is newly exciting
Linda:  Gilead - a snapshot  
Kristine:  M&A:  What does Pharma want?
Trevor:  Market Sentiment:  On more solid footing..


May 2024- Pullan's Pieces #203

Linda: IPOs of 2024
Linda:  Market cap per employee and other stats by territory  
Kristine:  Option Deals in BiotechTrevor:  Market Sentiment:  Marking Time?


April 2024 - Pullan's Pieces #202
Linda:  Radiopharmaceuticals
Linda:  Impact of orphan designation
Kristine:  Synthetic royalty structures
Trevor:  Market sentiment:  which way do we go?

March 2024- Pullan's Pieces #201
Linda:  Ono snapshot
Linda:  Competition and market share
Kristine:  ADCs
Trevor:  Market sentiment. PE around 18?

February 2024- Pullan's Pieces #200
Linda: India and Innovation
Linda:  Peptides
Kristine:  Vectors in Gene Medicines
Trevor:  Market Sentiment:  Risk-free rates of return?

January 2024- Pullan's Pieces #199
Linda: How different are different Therapeutic areas?
Linda:  BioNtech snapshot
Kristine:  2024 – A Turnaround Year
Trevor:  Market Sentiment:  Good news on earnings?


Pullan's Pieces

​​a free monthly email newsletter with analysis relating to biotech and pharmaceutical deals and trends.  


Click on the months below for a few samples and sign up here